Astellas Resumes XLMTM Gene Therapy Trials Following Previous Fatalities
Astellas is moving forward with its XLMTM gene therapy trials despite earlier reports of deaths. Meanwhile, Veradermics celebrates success in its hair loss pill trial, and the FDA accelerates reviews for psychedelics.
Astellas has decided to retry its XLMTM gene therapy after facing challenges related to patient fatalities in previous trials. This decision comes amid ongoing scrutiny and concern regarding the safety of such treatments.
In a related development, Veradermics has reported success in the late-stage trials of its hair loss pill, marking a significant milestone for the company and its potential market impact.
Additionally, the FDA is expediting its review processes for psychedelic substances, indicating a shift in regulatory attitudes towards these therapies. This could pave the way for more innovative treatments in the biotech sector.